Table 2.
Univariate analysis of demographic characteristics and COPD-related clinical data in group A and B patients
| Characteristics | Group A
|
Group B
|
Group A and B
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| ICS user | No ICS | P-value | ICS user | No ICS | P-value | ICS user | No ICS | P-value | |
| Patient number (%) | 54 (30.2%) | 125 (69.8%) | <0.001 | 144 (36.2%) | 254 (63.8%) | <0.001 | 198 (34.3%) | 379 (65.7%) | <0.001 |
| Sex (%) | |||||||||
| Male | 48 (88.9%) | 119 (95.2%) | 0.189 | 133 (92.4%) | 237 (93.3%) | 0.723 | 181 (91.4%) | 356 (93.9%) | 0.258 |
| Smoking history (%) | |||||||||
| Never | 4 (8.0%) | 6 (4.9%) | 0.578 | 18 (12.8%) | 24 (9.8%) | 0.110 | 22 (11.5%) | 30 (8.2%) | 0.049 |
| Ex-smoker | 27 (54.0%) | 61 (50.0%) | 86 (61.0%) | 131 (53.7%) | 113 (59.2%) | 192 (52.5%) | |||
| Currently smoking | 19 (38.0%) | 55 (45.1%) | 37 (26.2%) | 89 (36.5%) | 56 (29.3%) | 144 (39.3%) | |||
| CAT score (%) | |||||||||
| Median (quartiles) | 6 (4, 8) | 5 (3, 7) | 0.128 | 12 (8, 17) | 11 (7, 15) | 0.038 | 10 (5, 16) | 8 (5, 13) | 0.011 |
| <10 | 54 (100.0%) | 125 (100.0%) | NA | 43 (29.9%) | 94 (37.2%) | 0.142 | 97 (49.0%) | 219 (57.9%) | 0.040 |
| ≥10 | 0 (0.0%) | 0 (0.0%) | 101 (70.1%) | 159 (62.8%) | 101 (51.0%) | 159 (42.1%) | |||
| mMRC score (%) | |||||||||
| Median (quartiles) | 1 (1, 1) | 1 (1, 1) | 0.576 | 2 (2, 2) | 2 (2, 2) | 0.274 | 2 (1, 2) | 2 (1, 2) | 0.274 |
| <2 | 51 (100.0%) | 119 (100.0%) | NA | 18 (15.9%) | 37 (16.5%) | 0.890 | 69 (42.1%) | 156 (45.5%) | 0.470 |
| ≥2 | 0 (0.0%) | 0 (0.0%) | 95 (84.1%) | 187 (83.5%) | 95 (57.9%) | 187 (54.5%) | |||
| Bronchodilator responder (%) | |||||||||
| Yes | 6 (12.5%) | 12 (10.9%) | 0.772 | 17 (12.8%) | 23 (11.0%) | 0.618 | 23 (12.7%) | 35 (11.0%) | 0.560 |
| No | 42 (87.5%) | 98 (89.1%) | 116 (87.2%) | 186 (89.0%) | 158 (87.3%) | 284 (89.0%) | |||
| Wheezing (%) | |||||||||
| Yes | 22 (40.7%) | 29 (23.2%) | 0.017 | 63 (43.8%) | 73 (28.7%) | 0.002 | 85 (42.9%) | 102 (26.9%) | <0.001 |
| No | 32 (59.3%) | 96 (76.8%) | 81 (56.3%) | 181 (71.3%) | 113 (57.1%) | 277 (73.1%) | |||
Note: Bronchodilator responder was defined as an increase of 12% and 200 mL in the FEV1 or FVC after bronchodilator drug treatment.
Abbreviations: CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; ICS, inhaled corticosteroids; mMRC, modified Medical Research Council.